10-Q
Quarterly Report
DRUGS MADE IN AMERICA ACQUISITION II CORP. DMII DMIIR DMIIU
0001213900-25-112095
- Filed
- Nov 18, 2025 12:00 AM ET
- Period of report
- —
On SEC.gov
Financials in this filing
| Metric | Period | Value |
|---|---|---|
| Shares Outstanding | Q3 2025 · Nov 18, 2025 | 65.58M sh |
| Operating Cash Flow | Q3 2025 · Sep 30, 2025 | −$703.37K |
| Operating Cash Flow | Q3 2025 · Sep 30, 2024 | −$155.06K |
| Stockholders Equity | Q3 2025 · Sep 30, 2025 | −$17.28M |
| Stockholders Equity | Q3 2025 · Jun 30, 2025 | −$214.12K |
| Stockholders Equity | Q3 2025 · Mar 31, 2025 | −$176.05K |
| Stockholders Equity | Q3 2025 · Dec 31, 2024 | −$116.72K |
| Stockholders Equity | Q3 2025 · Sep 30, 2024 | −$6.68K |
| Current Liabilities | Q3 2025 · Sep 30, 2025 | $677.35K |
| Current Liabilities | Q3 2025 · Dec 31, 2024 | $254.78K |
| Total Liabilities | Q3 2025 · Sep 30, 2025 | $18.18M |
| Total Liabilities | Q3 2025 · Dec 31, 2024 | $254.78K |
| Current Assets | Q3 2025 · Sep 30, 2025 | $896.36K |
| Current Assets | Q3 2025 · Dec 31, 2024 | $59.62K |
| Total Assets | Q3 2025 · Sep 30, 2025 | $501.01M |
| Total Assets | Q3 2025 · Dec 31, 2024 | $138.06K |
| Sga Expense | Q3 2025 · Sep 30, 2025 | $155.51K |
| Sga Expense | Q3 2025 · Sep 30, 2025 | $252.91K |
| Sga Expense | Q3 2025 · Sep 30, 2024 | $41.68K |
| Net Income | Q3 2025 · Sep 30, 2025 | −$46.16K |
| Net Income | Q3 2025 · Sep 30, 2025 | −$143.56K |
| Net Income | Q3 2025 · Jun 30, 2025 | −$38.07K |
| Net Income | Q3 2025 · Mar 31, 2025 | −$59.33K |
| Net Income | Q3 2025 · Sep 30, 2024 | −$41.68K |
| Operating Income | Q3 2025 · Sep 30, 2025 | −$155.51K |
| Operating Income | Q3 2025 · Sep 30, 2025 | −$252.91K |
| Operating Income | Q3 2025 · Sep 30, 2024 | −$41.68K |